Adverum Biotechnologies

What Adverum Biotechnologies does

Adverum Biotechnologies was a clinical-stage gene therapy company headquartered in Redwood City, California, founded in 2006 and acquired by Eli Lilly and Company in December 2025. The company developed ixoberogene soroparvovec (Ixo-vec), an investigational gene therapy for wet age-related macular degeneration (wet AMD) that uses Adverum's proprietary AAV.7m8 adeno-associated virus vector capsid to deliver a codon-optimized aflibercept coding sequence to retinal cells via a single intravitreal injection, transforming those cells into biofactories that continuously produce anti-VEGF protein. The AAV.7m8 capsid includes a 10-amino acid peptide loop engineered to cross the inner limiting membrane and transduce retinal cells with approximately 5-fold greater efficiency than natural AAV2, with manufacturing conducted via the Baculovirus Expression Vector System (BEVS).

Ixo-vec was designed to address a primary unmet need in wet AMD: the burden of lifelong anti-VEGF injections every 4–8 weeks, which leads to missed appointments and progressive vision loss in up to 42% of patients within 2–3 years. In Phase 2 trials (OPTIC and LUNA), Ixo-vec demonstrated 81–94% reductions in annualized anti-VEGF injection burden sustained through 4 years, stable aflibercept protein levels out to 5 years, and 93% patient preference over prior anti-VEGF therapy at the pivotal dose. The company advanced Ixo-vec into ARTEMIS, the first-ever registrational intravitreal gene therapy Phase 3 trial, in March 2025.

Commercially, Adverum was pre-revenue with no approved products. Its go-to-market motion was being built around enterprise field sales targeting the approximately 2,000–3,000 US retina specialists who treat wet AMD, supported by FDA Fast Track and RMAT designations, EMA PRIME designation, and UK MHRA Innovation Passport. Following Eli Lilly's December 2025 acquisition, the business operates as a wholly-owned subsidiary of Lilly with future commercial distribution expected to leverage Lilly's global pharmaceutical infrastructure.

Name

Adverum Biotechnologies

Legal name

Adverum Biotechnologies, Inc.

Website

https://adverum.com

Company type

Public

Founded year

2006

Operating status

Acquired

Headcount range

101–250 employees

Short description

Adverum Biotechnologies was a clinical-stage gene therapy company developing Ixo-vec, a one-time intravitreal AAV.7m8 gene therapy for wet AMD that delivers sustained aflibercept expression, acquired by Eli Lilly in December 2025.

Ownership category

akta.pro rank

Product category

Ocular Gene Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Ocular gene therapy
• Wet AMD treatment
• Adeno-associated virus
• Intravitreal delivery
• Anti-VEGF therapy

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Ixo-vec Commercialization (Future): Pre-revenue clinical-stage company. Once Ixo-vec receives regulatory approval, revenue will be generated through product sales of the one-time intravitreal gene therapy for wet AMD. Market projections suggest gene therapies for wet AMD could exceed the current ~$10 billion global anti-VEGF market, with pricing scenarios ranging from $60,000 to $350,000 per patient.
2. Eli Lilly Acquisition: Company was acquired by Eli Lilly in December 2025 for approximately $74-262 million (including contingent value rights up to $12.47 per share). The acquisition provides Eli Lilly with Ixo-vec and Adverum's gene therapy platform for ocular diseases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Adverum Biotechnologies develops a single clinical-stage gene therapy product candidate, Ixo-vec (ixoberogene soroparvovec, ADVM-022), for wet age-related macular degeneration. Ixo-vec uses the proprietary AAV.7m8 vector platform to deliver a one-time intravitreal injection that transforms retinal cells into biofactories producing continuous therapeutic doses of aflibercept, an established anti-VEGF protein, aiming to replace the current standard-of-care regimen of frequent (every 4-8 weeks) eye injections with a single long-acting treatment.

Product overview

Adverum Biotechnologies is a clinical-stage company developing a single gene therapy product, Ixo-vec (ixoberogene soroparvovec), for wet age-related macular degeneration. The product utilizes the company's proprietary AAV.7m8 vector platform to deliver a one-time intravitreal injection that transforms retinal cells into biofactories producing continuous aflibercept, potentially replacing the current standard of care requiring frequent eye injections.

Differentiator

Problem solved

Functional benefit

Products and services

• Ixo-vec (ixoberogene soroparvovec, ADVM-022) A clinical-stage gene therapy candidate for wet age-related macular degeneration (wet AMD) that uses a proprietary AAV.7m8 vector capsid carrying an aflibercept coding sequence to enable retinal cells to continuously produce anti-VEGF protein from a single intravitreal injection, intended to replace frequent chronic anti-VEGF injections.

Quantifiable outcome

• 81-94% reduction in annualized anti-VEGF injection burden in Phase 2 trials through 4 years
• +6 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 24 October 2025Eli Lilly acquired Adverum Biotechnologies in October 2025 for up to $12.47 per share ($3.56 cash + CVRs up to $8.91). The acquisition gives Lilly Ixo-vec, a Phase 3 gene therapy for wet AMD, and Adverum's proprietary intravitreal AAV gene therapy platform. Transaction completed December 9, 2025. Lilly also provided a $65 million secured loan facility to support clinical development pending closing.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Regenxbio: Clinical-stage gene therapy company developing RGX-314, an AAV-based gene therapy for wet AMD, using sub-retinal delivery. Direct competitor to Ixo-vec in the ocular AAV gene therapy space with overlapping patient population and target customers (retina specialists).
• 4D Molecular Therapeutics: AAV gene therapy company with proprietary intravitreal vector platforms and ophthalmology pipeline targeting wet AMD and other retinal diseases. Closely comparable to Adverum in capsid engineering approach and intravitreal delivery modality.
• MeiraGTx: Clinical-stage gene therapy company with active ocular programs including treatments for wet AMD and inherited retinal diseases. Comparable in targeting the retina specialist channel and using AAV-based delivery approaches.

Broad incumbents

• Spark Therapeutics (Roche): Roche subsidiary that developed and commercialized Luxturna, the first FDA-approved gene therapy for an inherited retinal disease. Closest precedent for ocular gene therapy commercialization, regulatory navigation, and pricing dynamics relevant to Ixo-vec.
• Gyroscope Therapeutics (Novartis): Acquired by Novartis in 2021; developed GT005, an AAV-based gene therapy for geographic atrophy. Operates in the same retinal disease gene therapy space and was acquired by a major pharma, paralleling Adverum's exit trajectory.
• Genentech (Roche): Markets Lucentis (ranibizumab) and Vabysmo (faricimab), established anti-VEGF therapies for wet AMD. Represents the incumbent standard of care against which Ixo-vec's clinical differentiation and pricing premium must compete.
• Regeneron Pharmaceuticals: Markets Eylea (aflibercept) and high-dose Eylea HD, the dominant anti-VEGF therapies for wet AMD that Ixo-vec directly aims to displace. Owns the comparator arm in the ARTEMIS Phase 3 trial.
• BioMarin Pharmaceutical: Commercial-stage gene therapy company with FDA-approved products (e.g., Roctavian for hemophilia A). Provides a benchmark for AAV gene therapy manufacturing scale-up, regulatory navigation, and payer access strategy relevant to Ixo-vec's commercial trajectory.

Emerging players

• Krystal Biotech: Commercial-stage gene therapy company with proprietary AAV platform and FDA-approved Vyjuvek. Relevant comparator for AAV gene therapy commercial scaling, durable expression claims, and specialty distribution models.

Others

• Editas Medicine: CRISPR-based gene editing company that has partnered with Adverum for delivery technologies. Adjacent player in the broader gene therapy ecosystem and a partner rather than direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/avalanchebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds9 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adverum Biotechnologies